In just one week, nearly 7,000 individuals have used the tracker to report that they cannot access their medications, with brand name products containing semaglutide reported as being the most challenging to access
Despite this limitation, there is significant consumer demand for these drugs beyond their approved uses
Nevertheless, since the risk of cardiovascular and renal events will remain even with the use of GLP-1RA, there is a great deal of clinical interest in its combined use with SGLT2i and finerenone (Table 4)
These recommendations can enable healthcare professionals (HCPs) to better guide GLP-1 RA users toward lasting health improvements
P., Kumar, H., Lausvig, N
FDA Warning: RISK OF THYROID C-CELL TUMORS FDA Warning: RISK FOR ILEUS (INTESTINAL BLOCKAGE) (FDA 09/22/2023) References: Buckley ST et al (2018): Transcellular stomach absorption of a derivative glucagon-like peptide-1 receptor agonist